LIPO logo

Lipella Pharmaceuticals (LIPO) Company Overview

Profile

Full Name:

Lipella Pharmaceuticals Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

December 19, 2022

Indexes:

Not included

Description:

Lipella Pharmaceuticals focuses on developing innovative treatments for bladder diseases. The company aims to improve patient outcomes through its advanced drug delivery systems, targeting conditions like interstitial cystitis. Lipella's research emphasizes safety and effectiveness, striving to meet unmet medical needs in urology.

Key Details

Price

$2.70

Annual Revenue

$449.60 K(+144.08% YoY)

Annual EPS

-$6.16(-20.31% YoY)

Annual ROE

-118.13%

Beta

1.41

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 8, 2024

Analyst ratings

Recent major analysts updates

Apr 9, 24 Maxim Group
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Lipella Pharmaceuticals?
  • Does Lipella Pharmaceuticals pay dividends?
  • What sector is Lipella Pharmaceuticals in?
  • What industry is Lipella Pharmaceuticals in?
  • What country is Lipella Pharmaceuticals based in?
  • When did Lipella Pharmaceuticals go public?
  • Is Lipella Pharmaceuticals in the S&P 500?
  • Is Lipella Pharmaceuticals in the NASDAQ 100?
  • Is Lipella Pharmaceuticals in the Dow Jones?
  • When does Lipella Pharmaceuticals report earnings?
  • Should I buy Lipella Pharmaceuticals stock now?

What is the ticker symbol for Lipella Pharmaceuticals?

The ticker symbol for Lipella Pharmaceuticals is NASDAQ:LIPO

Does Lipella Pharmaceuticals pay dividends?

No, Lipella Pharmaceuticals does not pay dividends

What sector is Lipella Pharmaceuticals in?

Lipella Pharmaceuticals is in the Healthcare sector

What industry is Lipella Pharmaceuticals in?

Lipella Pharmaceuticals is in the Biotechnology industry

What country is Lipella Pharmaceuticals based in?

Lipella Pharmaceuticals is headquartered in United States

When did Lipella Pharmaceuticals go public?

Lipella Pharmaceuticals's initial public offering (IPO) was on December 19, 2022

Is Lipella Pharmaceuticals in the S&P 500?

No, Lipella Pharmaceuticals is not included in the S&P 500 index

Is Lipella Pharmaceuticals in the NASDAQ 100?

No, Lipella Pharmaceuticals is not included in the NASDAQ 100 index

Is Lipella Pharmaceuticals in the Dow Jones?

No, Lipella Pharmaceuticals is not included in the Dow Jones index

When does Lipella Pharmaceuticals report earnings?

The date for Lipella Pharmaceuticals's next earnings report has not been announced yet

Should I buy Lipella Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions